Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

February 24, 2026

NASDAQ US Health Care Biotechnology earnings 66 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Good afternoon, everyone, and thank you for being with us on today's call. Robert I. Blum, our President and Chief Executive Officer, is going to kick things off with a look at the quarter and what's happened recently. Andrew M. Callos, EVP and Chief Commercial Officer, will then talk about the U.S. commercial launch of MYCorzo as well as our launch readiness in Europe. Fady Malik, EVP of R&D, along with Stuart Kupfer, SVP and Chief Medical Officer, will share updates on our clinical development programs. Sung H. Lee, EVP and Chief Financial Officer, will walk through a financial overview for 2025 and go over our financial guidance for 2026. After that, Robert will return for closing remarks and a review of the key milestones ahead this year. Before we go further, please be aware that some portions of what we discuss, including answers we give to your questions, will contain statements tied to future events and performance instead of historical facts, and those constitute forward-looking statements. Among them are statements about the expected timing and possible outcomes of clinical trials, including ACACIA-HCM, expectations around regulatory interaction and the possibility of regulatory approval, expectations around commercial performance, and statements concerning our financial guidance and capital allocation. Actual results could differ materially from what those forward-looking statements project. You can find additional information about factors that might cause our actual results to differ materially from those in the forward-looking statements in our SEC filings, including our current report on our fourth quarter 2025 financial results, filed on Form 8-K and furnished to the SEC today, and our annual report, which we will file on Form 10-K in the coming days. We have no obligation to update any forward-looking statements after this call. I'll now hand the call over to Robert I. Blum.

Robert I. Blum

executive
#2

Thanks, Diane, and I appreciate everyone being with us on today's call. 2025 was a pivotal year for Cytokinetics, Incorporated, since the FDA cleared MYCorzo to treat adults who have symptomatic obstructive HCM — the very first drug we have taken all the way from discovery through to commercialization. In truth, within just one week, Cytokinetics, Incorporated secured approvals for MYCorzo in the U.S. as well as China, and also gained a positive opinion from CHMP regarding MYCorzo in the European Union; that last achievement came before last week's news that the European Commission had approved MYCorzo in the EU. All of this adds up to the result of many years of focused effort across science, clinical development, and regulatory affairs, and Cytokinetics, Incorporated is now starting a new chapter as a global biopharmaceutical firm operating at the commercial stage. What matters even more is that MYCorzo's approval gives patients with obstructive HCM—a serious disease that can have a profound impact on daily life—a new treatment option. As Andrew will describe, since the FDA gave its approval in December, our teams have stayed focused on executing a careful, methodical commercial launch. We remain focused on standing up the infrastructure, training, promotional efforts, and access-to-market routes that serve doctors, patients, and insurers, while at the same time building early and lasting launch speed and traction. It's still early days, but what we've achieved thus far gives us confidence, and so do the first interactions we're seeing with the cardiology field. In fact, enthusiasm for MYCorzo as a fresh treatment option is significant. As we consider the longer-range U.S. commercial launch path, we submitted the supplemental NDA for MAPLE-HCM to the FDA in the first quarter. We expect the FDA to complete its review of the sNDA in Q4 2026. There's a chance that folding the MAPLE-HCM findings into a wider indication for MYCorzo could strengthen and expand how deeply and broadly the category gets adopted, which would let a greater number of patients eventually see the benefits. Along those same lines, we're of course eager for the ACACIA-HCM data to come out in non-obstructive HCM, and a top line announcement is still scheduled for the second quarter of this year. nHCM represents its own separate patient group with a significant level of unmet medical need. Should that study produce positive results, it could additionally become a possible growth driver for MYCorzo. Outside America, following the EU's recent green light for MYCorzo, we've shifted into completely carrying out our plans to get ready for commercialization, and our inaugural launch is set to happen in Germany during Q2. Also, in last year's fourth quarter, Health Canada agreed to examine the New Drug Submission for aficamten, so an approval for aficamten in Canada might come later in the year. Looking forward, we're stepping into this next stage of our company's evolution with considerable momentum as well as robust finances. What we accomplished last year puts us in a good spot for ongoing expansion and generating value, even as we continue watching our capital structure and how we allocate capital. Sung is going to cover our financial guidance and where we stood at the close of 2025, along with operating expense guidance for 2026; that outlook mirrors what matters most to us — getting MYCorzo launched and moving our muscle biology pipeline forward — while executing with discipline and keeping an eye on capital efficiencies. The foundation we're putting in place for our specialty cardiology franchise gives us confidence, and so does our ability to deliver for patients and shareholders alike. At this point I'll hand the call over to Andrew.

Andrew M. Callos

executive
#3

Thanks, Robert. Right after the FDA cleared MYCorzo in December, we kicked off our U.S. commercial launch. We designed our customer support infrastructure around a group of HCM navigators who work with patients individually. Within days of that approval, these navigators were already answering calls, which meant patients and HCPs had help available. Right after the December FDA approval, we rolled out our marketing efforts aimed at patients and HCPs, using surround-sound assets and activations like quick start guides, patient brochures, websites, and social media advertising to build awareness and educate patients. Our sales reps, known internally as Cardiovascular Health Specialists, started talking with HCPs right after the New Year's holiday and getting certified within the MYCorzo label. Only a short time passed after the approval before the MYCorzo REMS online portal became operational, allowing prescriptions for MYCorzo to be issued. On that very date, we launched "Corzo & You," the patient support initiative we created to deliver individualized assistance, access help, reimbursement support, and affordability choices for patients who qualify — including a free trial offering, a bridge program, co-pay assistance, and a patient assistance program. As soon as the product became available in channel on day one, HCPs began obtaining REMS certification while patients started enrolling in Corzo & You. Several days following its availability, the initial MYCorzo prescriptions were dispensed. During January, we additionally conducted our inaugural national speakers' broadcast, which attracted robust participation from across the U.S. That marked only the start of something that will expand into a wide-ranging peer-to-peer education initiative for physicians — an essential component of how we intend to ensure healthcare professionals are aware of this newly available therapy. All of these combined commercial launch efforts were scheduled to debut in unison and support our bold objectives for MYCorzo within the United States. We remain at an early stage of the launch, though responses from customers have been favorable to this point. There's clear excitement among HCPs about gaining another cardiac myosin inhibitor to use in treating obstructive HCM, and what draws particular attention is the clinical data demonstrating lasting decreases in obstruction alongside symptom improvement, without any patients stopping treatment because of ejection fraction reductions, as observed in SEQUOIA-HCM. Based on our understanding, many HCPs also appreciate being able to dose flexibly and titrate quickly, potentially every two weeks, along with a monitoring schedule that can be adjusted so echos happen anywhere from two to eight weeks out, plus the absence of any requirement for drug-to-drug interaction counseling under the MYCorzo REMS. The launch remains at an early stage, yet the initial engagement, REMS certification, and overall demand look encouraging. Over 700 HCPs across HCM specialty and non-specialty centers became REMS-certified within three weeks — an early signal that HCPs intend to prescribe MYCorzo; and, as noted earlier, patients were receiving therapy during the first week MYCorzo was available. The demand we're seeing in REMS patient enrollments and therapy thus far makes us even more confident about MYCorzo's commercial potential. On top of that, over 12,000 customer engagements have been recorded already, a number that reflects our Cardiovascular Account Specialists connecting with more than 95% of the 700 HCPs who currently drive the majority of CMI prescribing. At this point, our efforts are centered on educating HCPs about the prescribing information, preparing them for what the REMS requires, and encouraging them to identify appropriate patients for MYCorzo. Market research conducted after launch revealed that, when no prompt was given, 90% of surveyed HCPs are aware of MYCorzo, and the majority indicated they plan to prescribe MYCorzo for patients dealing with obstructive HCM. They likewise mention that they recognize possible benefits tied to the MYCorzo clinical profile regarding efficacy, safety, and tolerability, along with the differentiated REMS and flexible dosing. Starting with our Q1 earnings call, as we've stated, we'll report three key metrics to measure how quickly and strongly our launch is progressing: how many HCPs are actively writing prescriptions, the number of prescriptions written by an HCP, and the count of patients taking MYCorzo. In our view, these serve as leading indicators of launch depth and breadth that will mirror our overall progress. As the launch moves forward, our goal for MYCorzo is to capture over 50% of CMI new patient preference share by 2026. Additionally, we intend to expand the entire CMI category. Our confidence rests on three factors tied to the launch: data from clinical trials, our customized patient assistance offerings, and the distinctive features of our REMS initiative. To begin with, findings from SEQUOIA-HCM demonstrate that MYCorzo produces swift and lasting decreases in obstruction along with better symptom relief; it allows dosing adjustments starting at just two weeks, with a monitoring plan that is flexible for both individuals receiving treatment and HCPs; and it showed no association with pauses in therapy or incidents of clinical heart failure. Next, through Corzo & You, our support initiative for patients, individuals gain one dedicated contact who provides an experience that merges compassion and personal rapport with reliability and a smooth, uninterrupted process. Third, the MYCorzo REMS program gives prescribers room to adjust the dose starting at two weeks. After the first dose and after any later change in dose, an echo needs to be done sometime between weeks two and eight. There's no DDI monitoring required. And crucially, once each echo is complete, the patient's dose can be titrated right away without waiting. Those three things at launch, in our view, will drive MYCorzo adoption and preference share. Another top priority is getting patients access. Well before the FDA approved the drug, we had already been talking with payers, sharing what our clinical trial showed and explaining both the clinical and economic toll that obstructive HCM takes. Earlier this year, right after approval, we sat down with every major payer. What we're aiming for is Medicare coverage on par with Camzyos during Q1, and commercial coverage matching Camzyos by the fourth quarter of 2026. Now to Europe: MYCorzo has secured EC approval throughout the European Union, so we're moving quickly toward our first commercial launch there, which will happen in Germany and is scheduled for Q2. Our commercial and medical teams in Germany are already in place, and our launch preparations are accelerating. Beyond that, we've brought on country leads across every EU4 nation plus the UK, getting ready for the European launches that will follow in late 2026 and during 2027; on top of that, we keep driving forward with commercial readiness work in Europe, which includes getting HTA dossiers ready for every major market there. Having the chance to bring MYCorzo to patients around the world is a real privilege, and building awareness along with confidence stands as our top priority. Other launches have shown that doing the early legwork on awareness and confidence in access matters greatly for unlocking momentum and velocity over the long haul. Initial engagement has us feeling positive, and our focus is on turning those engagements into steady, scalable execution with solid commercial results as the year goes on. With all that said, I'll hand things over to Fady, who will walk through our medical and clinical development work.

Fady Malik

executive
#4

Thanks, Andrew. To help drive the MYCorzo launch, our medical affairs group kept broadening the way it works with the HCM community both before and now throughout our commercial launch. For a number of years now, the field medical affairs team has been in place, collaborating with our clinical trial sites while SEQUOIA-HCM and MAPLE-HCM were being conducted, and forging strong ties throughout the HCM community. As soon as MYCorzo was approved, our U.S. field medical teams—Therapeutic Medical Scientists and Managed Health Medical Scientists among them—had finished their training and were up and running, which let them get off to a fast start and begin engaging in 2026. Since the approval, our U.S. TMS team has quickly ramped up scientific engagement, carrying out more than 500 interactions with HCPs to support MYCorzo. Working alongside our U.S. payer account managers, our U.S. MHMS team has broadened its engagement by carrying out over 50 access-related interactions, underscoring the economic profile, clinical profile, and safety considerations that matter most to those making access decisions. At next month's ACC, our presence will highlight our leadership in HCM, with accepted oral and poster presentations that address real-world treatment implications, further data from MAPLE-HCM, and key safety and efficacy analyses taken from our late-stage clinical programs. In line with our global development strategy, our partner Bayer finished enrolling patients in CAMELLIA-HCM, a Phase 3 clinical trial of aficamten in Japanese patients who have obstructive HCM. On top of that, we finished enrolling the Japanese cohort of non-obstructive HCM patients in ACACIA-HCM, and both are meant to support a possible marketing authorization for aficamten in Japan. In the fourth quarter, we shared further data from MAPLE-HCM across three late-breaking sessions at the HCM Society Scientific Sessions and the Scientific Sessions. Responder analyses demonstrated that a significantly larger number of patients taking aficamten had a positive response than did patients taking metoprolol. What's more, treatment with aficamten produced significantly greater improvements than metoprolol did on symptoms and cardiac biomarkers. The findings from MAPLE-HCM have struck a strong chord throughout the cardiology community, bringing attention to how thinking is evolving about standard-of-care treatment in HCM and the need for new therapies. I'll now turn things over to Stuart, who will talk more about ACACIA-HCM along with our continuing development programs in heart failure.

Stuart Kupfer

executive
#5

Thank you, Fady. The upcoming key data release we have will be from ACACIA-HCM, our pivotal Phase 3 study of aficamten in nHCM patients. We're still set to report top line results for the primary cohort, leaving out Japan, during the second quarter. We expect that the top line press release will stay fairly high level, so we don't risk the full results being presented at a possible medical congress later in the year. nHCM represents a patient group with substantial unmet need and no approved treatments. We're eager to share the ACACIA-HCM findings and to assess whether aficamten can show a clinically meaningful benefit for these individuals. Like any pivotal trial, a variety of outcomes could occur, and we'll offer a comprehensive review of the data at an upcoming medical congress after the top line release. As we've said before, ACACIA-HCM is being run within its design parameters, and closeout is proceeding as planned. Because of our know-how and track record in designing and running HCM trials, we think we've successfully carried out a well-designed clinical trial. We stay confident in ACACIA-HCM and look forward to the second quarter results. Now turning to our heart failure clinical development programs. In the quarter, we kept running COMMUN-HF, the confirmatory Phase 3 trial of omecamtiv mecarbil in patients who have symptomatic heart failure with severely reduced ejection fraction below 30%. At this point, 100% of U.S. sites are activated, along with more than 90% of European sites. We'll soon broaden the trial into China to grow the global footprint of this important clinical trial. We also kept going with AMBER-HFpEF, the Phase 2 trial of olicamtiv, in patients with symptomatic heart failure with preserved ejection fraction of at least 60%; enrollment continued in cohort one of AMBER-HFpEF, and we expect it to be completed this first quarter. Once an interim safety review takes place, we may evaluate whether to start enrolling in cohort two to assess a higher dose. We're encouraged by the ongoing progress and execution across these active clinical trials, which reinforces our emphasis on disciplined development and advancing innovative medicines in our emerging specialty cardiology franchise. With that, I'll hand it over to Sung. Thank you, Stuart.

Sung H. Lee

executive
#6

We're happy to share the financial results for our fourth quarter and the full year 2025. Let's begin with the balance sheet: as of the end of 2025, we held roughly $1,220,000,000 in cash, cash equivalents, and investments, down from $1,250,000,000 at the close of 2024. Within that 2025 year-end figure is $100,000,000 in proceeds from drawing on tranche five of the Royalty Pharma multi-tranche loan. If you set aside those loan proceeds, cash, cash equivalents, and investments would have fallen by about $134,000,000 over the course of 2025. Now to the income statement: Q4 2025 total revenues came in at $17,800,000, versus $16,900,000 during the same quarter in 2024. For the full year 2025, total revenues reached $88,000,000, compared with $18,500,000 in 2024. The full-year 2025 total revenues mainly reflected the successful completion of the technology transfer to Bayer, which brought in $52,400,000 during 2025, along with recognition of $15,000,000 in milestones in 2025 tied to approvals of MYCorzo in the United States and China under the Sanofi license agreement. As we've said before, MYCorzo reached patients around January, so we anticipate reporting product sales of MYCorzo alongside our Q1 2026 results. Fourth quarter R&D expenses totaled $104,400,000, compared with $93,600,000 for the same period in 2024. Full year 2025 R&D expenses were $416,000,000, compared with $339,400,000 in 2024. The rise from 2024 to 2025 largely reflected progress in our clinical trials, greater personnel-related costs such as stock-based compensation, and medical affairs activities. Q4 2025 G&A expenses were $91,700,000, compared with $62,300,000 for the same period in 2024. Full year 2025 G&A expenses came to $284,300,000, compared with $215,300,000 in 2024. The growth from 2024 to 2025 stemmed mainly from investments in commercial readiness, including hiring our U.S. sales force largely during 2025, plus higher non-sales personnel-related costs. Net loss for Q4 2025 was $183,000,000, or $1.50 per share, versus a net loss of $150,000,000, or $1.26 per share, for the same period in 2024. Full year 2025 net loss was $785,000,000, or $6.54 per share, versus a net loss of $589,500,000, or $5.26 per share, in 2024. Let's move to our financial guidance for 2026. Since this marks our first year launching MYCorzo, we aren't offering product sales guidance right now; on the expense side, we anticipate GAAP combined R&D and SG&A expense landing between $830,000,000 and $870,000,000. Stock-based compensation within that GAAP combined R&D and SG&A expense should fall between $120,000,000 and $130,000,000. Taking stock-based compensation out of the GAAP combined R&D and SG&A expense gives a range of $700,000,000 to $750,000,000. When we talk about the GAAP figure that combines R&D with SG&A, a few things are left out. One is collaboration costs, which takes in reimbursed amounts as well as the expense tied to inventory sales of aficamten to our partners. Another is any potential spending on commercializing aficamten in nHCM, which depends on how ACACIA-HCM reads out and on regulatory review. And the third is whatever impact GAAP adjustments might have from events happening after this guidance is published — that covers business development activities, among other things, though not only those. On capital allocation, here's how we're prioritizing. Number one: the MYCorzo launch in the U.S., plus paying for commercial readiness work in Europe. Number two: moving the pipeline forward, meaning the significant label expansion chances for aficamten along with the omecamtiv mecarbil and olicamtiv trials that are underway. Number three: putting money into our muscle biology platform and pipeline. As we begin operating as a commercial-stage company around the world, we'll stay disciplined about how we allocate capital and keep acting as solid stewards of it. With that, I'll turn things back over to Robert.

Robert I. Blum

executive
#7

Thanks, Sung. Before we open the floor to questions, I believe it's worth pausing to reflect on what this moment signifies for Cytokinetics, Incorporated. After years of dedication, rigor, and steadfast devotion to our science, we've moved past an essential milestone — from chasing what might be possible to actually making a difference. With MYCorzo approved, a new chapter begins, one in which our efforts shape patients' everyday experiences and the choices clinicians make worldwide. At Cytokinetics, Incorporated, we've spent close to 28 years building toward this, and it stands as proof of relentless perseverance, commitment, and a disciplined drive to turn our science into medicine that helps patients. That shift brings with it a stronger feeling of purpose and commitment to the principles we hold dear, the ones that shape the way we work. At the top of that list sits our belief that “Patients are our North Star.” In Q4, we shared that we're backing a three-year effort spearheaded by the American Heart Association focused on inequities in care access, diagnosis, and treatment for those dealing with HCM. This long-standing pledge reflects our hope of helping narrow the distance between evidence, guidelines, implementation, and fairness in how HCM care gets delivered. What matters at this point isn't just innovation — it's also the duty we have to stand up for patients and the communities we serve. Everything we've covered in this discussion represents the culmination of years of concentrated effort throughout the company — spanning discovery, development, regulatory affairs, manufacturing, and, at this point, commercial launch activities. The foundation that allowed us to reach this point came from our team members' steadfast commitment and enthusiasm, and my appreciation for them knows no bounds. Looking ahead to this new phase, with the company now operating at the commercial stage, our priorities haven't changed: pursue bold execution, keep moving our pipeline forward, and generate substantial, durable benefits for the people we serve and for our investors. At this point, let me walk through what we've targeted for 2026. Regarding aficamten, we anticipate sharing topline data from ACACIA-HCM during the second quarter of 2026. For MYCorzo, our expectation is a Germany launch in the second quarter of 2026. Looking ahead, we anticipate that the FDA could grant approval for the supplemental NDA covering MAPLE-HCM around the fourth quarter of 2026. Enrollment for the adolescent group in CEDAR-HCM should wrap up during Q4 2026, and we're expecting a possible green light from Health Canada within the latter half of this year. Turning to omecamtiv mecarbil, our plan is to keep enrolling patients and running COMMUN-HF throughout 2026. As for olicamtiv, cohort one of AMBER-HFpEF should finish enrolling in the first quarter of 2026, with cohort two of AMBER-HFpEF reaching full enrollment at some point in 2026. Lastly, on the preclinical and research side, we intend to carry forward our existing preclinical work along with research efforts aimed at further programs centered on muscle biology. Operator, at this point we're ready to take questions from participants, if you'd please begin that now.

Tessa Romero

analyst
#8

Hi there, good afternoon, Robert, and everyone on the team. We really appreciate you giving us this time today. So, our first question is about ACACIA. Is it correct that the trial counts as a success as long as a minimum of 1 of the endpoints achieves statistical significance? And following that, within your protocol for the study, did you state in advance which endpoint would have to be achieved in order to legitimately declare success? Put another way, is it KCCQ or peak VO2, or does either one work? Thank you.

Robert I. Blum

executive
#9

I'll kick things off, and then I'll hand it over to Fady and Stuart. When you're defining success, you also need to think about who you're dealing with; and clearly, the clinical community will have its own expectations and interests, and so might FDA, and those could differ; but it's accurate that in the way we've built this clinical trial, it will be considered positive if it achieves either one or both of the prespecified clinical trial endpoints; with that said, I'll also pass it to Fady and Stuart in case they'd like to add something.

Fady Malik

executive
#10

My view is that we should also note this: both outcomes would be seen as just as favorable.

Robert I. Blum

executive
#11

If either one comes back positive, then the trial counts as positive. Neither carries more weight than the other.

Roanna Ruiz

analyst
#12

Good afternoon, everyone. Hello there. So I have a question. I've been thinking about MYCorzo and how it was first introduced with regard to engaging cardiologists. Could you give us any sense of how much time it's taking for sites and clinical centers to complete the REMS certification and begin prescribing? Are the field reps seeing anything thus far when they detail?

Robert I. Blum

executive
#13

I'll begin once more, then hand things to Andrew. And we deliberately are putting emphasis on engagements, or inputs, on today's call since we're at an early stage of the launch. But we truly are impressed by the number of HCPs who are already REMS-certified and how quickly that occurred soon after the product reached channel. And I'll have Andrew go into more detail.

Andrew M. Callos

executive
#14

Absolutely. The REMS certification involves a brief self-guided module plus a scored quiz of 10 questions, as you might already know. Typically, it takes a cardiologist 10 to 20 minutes, and at times it's done even quicker. So being REMS-certified really hasn't proven to be an obstacle. My sense is that plenty of HCPs and cardiologists with whom we spoke had been awaiting approval for MYCorzo, and their patients had been waiting too, and we've seen robust involvement from a wide range of cardiologists, inside as well as beyond centers of excellence, not just when it comes to REMS certification but also in getting patients REMS-certified and prescribed; and, further, given that this is now the second cardiac myosin inhibitor rather than the first, those cardiologists already knew what a REMS entailed and were expecting one, so once we launched and had product available in the channel, I believe they were ready and well-positioned to complete REMS certification rapidly, and we are witnessing that.

Roanna Ruiz

analyst
#15

Got it. Thanks.

Robert I. Blum

executive
#16

Hello, Mayank.

Mayank Mamtani

analyst
#17

Yes. Good afternoon, everyone. We appreciate you fielding our questions, and congratulations on what has been a highly productive stretch of late. So regarding ACACIA, if I could, might you share what you anticipate for the placebo group on both KCCQ and peak VO2? And would you look for that to line up with what prior nHCM trials have shown? Also, could you weigh in on whether a reduction in NT-proBNP comparable to what appeared in the earlier OLE experience would be expected at the time point you have here, and do you think that would track with the exposure you might get from a dose intensity standpoint?

Robert I. Blum

executive
#18

I will turn to my colleagues to address your question, but let me remind both you and them that since we are nearing the end of the study, and since we anticipate moving toward database lock and unblinding, our response to your question ought to concern what the original design expectations were; and I want to be sure we are not, in any manner, getting ahead of anything that could be gleaned about how the trial is progressing, as opposed to its design and conduct.

Fady Malik

executive
#19

One thing we need to keep in mind is that the data remains blinded to us, meaning we genuinely have no idea how the placebo arms are performing; however, drawing on what we've seen before, the placebo response in the peak VO2 arm tends to be roughly zero.

Robert I. Blum

executive
#20

It could come in slightly above or slightly below that, yet in the studies we ran before, when it comes to placebo response — peak VO2 doesn't really show much of one, and once more, ACACIA's design was grounded in —

Fady Malik

executive
#21

A response to placebo that matches what we saw in our earlier trials. You know, figure on four to five points, maybe six points. But just to —

Robert I. Blum

executive
#22

I want to stress that how the study was statistically designed doesn't depend on how large the placebo response turns out to be. What it depends on is the gap between the active —

Fady Malik

executive
#23

We also looked at how patients responded to the treatment versus how they responded to placebo. For the KCCQ, which served as the basis for our power calculation, that gap came out to 5 points —

Robert I. Blum

executive
#24

The distinction we observed between the placebo group and the active treatment group. And then, if I'm not mistaken, the final item you raised had to do with NT-proBNP.

Fady Malik

executive
#25

We certainly would not have any —

Robert I. Blum

executive
#26

What we anticipated diverges from what we actually saw in Phase 2 or the open-label extension regarding the way NT-proBNP has gone down while patients received aficamten, though those data remain blinded to us too.

Mayank Mamtani

analyst
#27

Thank you, team.

Robert I. Blum

executive
#28

Hey, Joe.

Joe Pantginis

analyst
#29

Hi, everyone. I appreciate you taking my questions. I'd like to ask about how the market is responding early on, and I'm happy Andrew said something earlier that I was also hoping to bring up. First, concerning the United States, Andrew, you mentioned — and had said previously — something regarding patients that physicians have been having in — I'd like to find out whether any of that uptake struck you as being on track or perhaps even faster than you'd anticipated. And then second, when it comes to outside the U.S., say China, for instance, how would you characterize any commercial distinctions? I understand you've begun building a team in that country, or what possible headwinds might you foresee there compared with what you'd encounter in the United States? Thank you.

Robert I. Blum

executive
#30

Andrew, would you like to handle that?

Andrew M. Callos

executive
#31

Okay, perhaps it makes sense to work in reverse. In China, Sanofi is the partner handling commercialization. That is not something we are doing ourselves. So this is a key point. Turning to U.S. patients in reserve, I believe the level of demand we are observing, and where it is coming from, matches our expectations. So the patient demand has not caught us off guard. I think this will show up in the research we were seeing during primary market research before approval — for example, demand studies and awareness studies — indicating there was widespread awareness. Physicians clearly knew about not only SEQUOIA but also MAPLE, both of which were presented at congresses; so I think we are where we anticipated being, given that we have had product on the market for roughly three weeks.

Robert I. Blum

executive
#32

I might just build on what Andrew said regarding market research, and additionally, since Wall Street equity research analysts have conducted surveys of their own, it was clearly shown that penetration in the existing cardiac myosin inhibitor category reached only 15% to 20% at the very most, leaving a substantial patient population that could still qualify for therapy. What we were told, and what the analysts were told, is that quite a few patients could be put on treatment right away, and initial signals indicate some patients had been kept waiting in anticipation of a possible approval; we'll be able to say more on that when the time comes.

Joe Pantginis

analyst
#33

Thanks.

Cory Kasimov

analyst
#34

Hi, Robert. Hi, everyone. I appreciate you fielding this. I had a follow-up regarding ACACIA, and I also wanted to ask about those two primary endpoints, KCCQ and peak VO2, with U.S. investigators specifically in mind. From a domestic perspective, is there a sense that one of these endpoints carries more weight than the other? I realize the original primary was KCCQ — does that tell us something about how American physicians view this? And along those lines, I understand how it's powered, but from a physician's standpoint, what magnitude of change would be viewed as clinically meaningful? Thanks.

Robert I. Blum

executive
#35

Once again, I want to remind everyone that the reason we opted for co-primary endpoints was not that we initially believed one mattered more than the other, but instead because the regulators preferred to see consistency throughout the trial, which was best accomplished by giving equal weight and emphasis to both co-primaries. Fady and Stuart, perhaps I could ask whether either of you would like to add anything.

Fady Malik

executive
#36

I'd just like to mention that, in my view, doctors won't favor one option over another. My sense is that they'll consider all the evidence available, including not only the primary endpoints but the secondary ones as well, which cover NYHA class along with other measures of exercise, biomarkers, and similar factors. So, as you know, within this area, no therapies exist for non-obstructive HCM. Clinicians want to see their patients' condition improve, and there are numerous dimensions —

Robert I. Blum

executive
#37

On top of that, they can make improvements, and, you know, I believe both they and regulators are going to consider the full picture of the data. Regarding your question about minimally important differences, for this situation in HCM, and to repeat what Fady said, no drug has been approved for these patients within this population. What will be viewed as important and clinically meaningful will hopefully depend on this trial, as we find out what is concordant — how the endpoints move together, and what in the end defines larger magnitude improvements versus what might be otherwise. So I believe we will learn a great deal from this study that will inform the clinical literature and hopefully what ultimately may become medical guidelines. But there are no reference standards or benchmarks we can point to. Rather, this study is meant to test those hypotheses and determine what ought to be important and meaningful.

Cory Kasimov

analyst
#38

That's useful, thanks to you both.

Salim Syed

analyst
#39

Thanks for taking the question, everyone. Ours is really about the disclosure. When you referred to it as high level, should we picture something closer to the way Bristol handled their Odyssey press release, which was entirely qualitative? My recollection is it was a single sentence, something like, the dual primaries were not met. Or should we picture something closer to SEQUOIA, the way you all did it, which was packed with numbers, or perhaps something in the middle? And if it does end up entirely qualitative, would you be open to addressing each of the co-primaries in that press release? Thank you.

Robert I. Blum

executive
#40

In the end, that comes down to the data and what gets judged material, and additionally, once those data arrive, what is negotiable with the medical congress. Putting out more would be a goal provided that doing so still allows for a full presentation at a significant medical meeting. With SEQUOIA, we did put out more, yet that came at the cost of being able to present at the medical congress where it would have fit better. So our preference is to manage both: share as much as possible while keeping the chance to present at the right next-level congress. Should it end up leaning more qualitative, my guess is we would need to address both endpoints. Speaking to just one and ignoring the other does not seem feasible to me. As for whatever else would be included past that, I believe everything hinges on the data, the size of the effect, p-values, and what we are able to make possible at a congress. Fady, is there anything you would like to add?

Fady Malik

executive
#41

How the data gets presented matters a great deal to academics, and looking back, I'd point to how MAPLE was shown at last year's ESC Congress — in that respect, it landed with enormous impact. So this involves a lot of factors and significant trade-offs —

Salim Syed

analyst
#42

From the standpoint of every party with a stake in this.

Robert I. Blum

executive
#43

We completely recognize how much these data matter, and that applies both to those in medicine and to those on Wall Street. And our aim is to give it our utmost effort.

Salim Syed

analyst
#44

Okay, that makes sense. Many thanks, everyone.

Yasmeen Rahimi

analyst
#45

Thanks a lot for all the detail. My question also relates to ACACIA. I believe one thing people keep asking us is whether you've completed payer research or uptake research to figure out if usage would remain robust if you demonstrated a three-point difference in KCCQ adjusted for placebo, or merely the commentary — provided there is statistical separation, how large the delta in KCCQ happens to be doesn't matter. I appreciate the detail, and I'll rejoin the queue.

Robert I. Blum

executive
#46

That may be something for both Fady and Andrew. Regarding your particular example of a three-point KCCQ difference, I imagine you chose that figure randomly. But perhaps, Fady and Andrew, you'd like to address it.

Fady Malik

executive
#47

To kick things off, what we observe across MAPLE and SEQUOIA is a spectrum when it comes to how strongly patients respond. So even though the typical response—take your case of three as an illustration—might reflect an average across all comers, there are those whose responses are considerably bigger, and clearly, certain patients show hardly any response whatsoever.

Robert I. Blum

executive
#48

And so I think in a lot of ways, the —

Fady Malik

executive
#49

The typical figure that emerges from the trial is definitely going to shape the way physicians perhaps view how significant the results are, but —

Robert I. Blum

executive
#50

Additionally, we had 500 patients join the trial, and a large number of those individuals will move into an open-label extension, and —

Fady Malik

executive
#51

A lot of these investigators are going to get the opportunity to make that judgment themselves — has the patient gotten better? And ultimately, I believe this probably comes down to: if you give it a try and you see a sizable response, and that matters to you, then you keep going with therapy; and if that does not happen, then continuing therapy is not something you have to do. And this is somewhat unlike drugs, where the goal of treatment is lowering risk, where you do not truly know whether you are the person who will gain from the drug, and because of that, absolute differences matter much more when it comes to grasping what benefit you might potentially receive.

Robert I. Blum

executive
#52

So I hope that helps from a medical perspective. Fady.

Andrew M. Callos

executive
#53

When we look at it from the perspective of demand, assuming the trial is statistical and MYCorzo gets approval for non-obstructive, the need for care goes up quite a bit, you know, considerably higher. We hear, for instance, that HCPs would be able to prescribe a single product across the whole of HCM, without having to worry about whether it's oHCM or nHCM, particularly with the profile that you know and that we know comes out of SEQUOIA; that would increase usage in oHCM, clearly, and in nHCM too. So it makes a big difference for nHCM, and possibly not a big one, but certainly some difference for oHCM as well.

Robert I. Blum

executive
#54

And I think, to wrap this up, just reaching clinical significance on its own isn't sufficient. The size of the change has to be meaningful, particularly when you're dealing with something like KCCQ, which has a documented history of placebo effect. So what we're aiming to show through this trial is a meaningful effect on KCCQ that goes beyond any placebo effect.

Jim Condulis

analyst
#55

Good afternoon. Congratulations on everything that's been accomplished, and thank you for fielding my question. I actually wanted to ask about HFpEF, and I was wondering, when it comes to ACACIA, how significant or meaningful do you believe a win in ACACIA would be in terms of helping to de-risk that larger HFpEF opportunity, given that there's some overlap in the pathology involved here? And I'm also curious whether you could help lay out when we might get a first look at data there and what constitutes a win. Thanks so much.

Robert I. Blum

executive
#56

That's a good question, and I'm going to have Stuart weigh in, but I'd also point out that we gained a great deal from what those ODYSSEY data can tell us. And that clearly carries impact and implications for what we're hoping to observe with our trial, ACACIA. But as you suggest, ACACIA could additionally shed light on what we may anticipate from HFpEF and how this cardiac myosin inhibitor mechanism translates into a neighboring population. That's definitely our aim; and with that, I'll turn it over to Stuart for his thoughts.

Stuart Kupfer

executive
#57

Thanks, James. You brought up a key body of evidence that genuinely shaped this hypothesis regarding what a CMI might offer patients who have HFpEF and, more specifically, those with hypercontractility. So, as you know, a lot of the structural characteristics overlap between patients who have non-obstructive HCM and those with HFpEF plus hypercontractility; therefore, I believe what comes out of ACACIA could shed further light on what a CMI might offer in HFpEF. As for the timing of when we expect results from AMBER-HFpEF, I'd say it's a bit too early to make that call, though we'll keep you updated regarding how the trial is progressing.

Robert I. Blum

executive
#58

To emphasize the point Stuart made regarding hypercontractility, I want to make sure everyone understands that our approach to HFpEF does not cover that whole patient population—only those individuals whose condition and anatomy are characterized by hypercontractility. That is precisely where we see a connection to nHCM. Thanks for asking that. Our following question is from Jason Butler at Citizens. Go ahead, please.

Jason Butler

analyst
#59

Hi, and thanks for taking my question. I was just hoping you might share some detail about which centers are currently enrolling in the REMS program. Are there any health care prescribers coming in who aren't presently CMI prescribers, or who have never written a CMI prescription before? Or would it be accurate to say that most of those signing up already prescribe CMI?

Andrew M. Callos

executive
#60

Appreciate the question. Most of them do already prescribe CMI, though we do have prescribers who hold REMS certification but aren't CMI prescribers at this time, and we also have some who are prescribing CMI for the first time. Still, just as you'd expect, the bulk of them are existing CMI prescribers.

Robert I. Blum

executive
#61

This aligns with how our Cardiovascular Account Specialists are directing their efforts. As Andrew noted during his prepared remarks, our work has become more concentrated on those targeted cardiologists who already prescribe at high volumes, and that's the context in which he discussed percent engagements. Still, it's encouraging to observe that beyond that group, a cardiac myosin inhibitor is already being used in places where it hadn't been before.

Jason Butler

analyst
#62

Great, thank you.

Maxwell Skor

analyst
#63

Thanks for the opportunity to ask. If ACACIA comes back positive, what kind of additional boost might we see to the obstructive HCM launch momentum in 2026? If you're able to put a number on it, or even offer a rough guess, that would help us model it. Also, should we expect ACACIA data in the first part of Q2, or is it more likely to come later in the quarter? Thanks.

Robert I. Blum

executive
#64

I'll take the second one and let Andrew handle the first. We won't say where in the second quarter that will land. I figure the analysts are going to run their own calculations, form their own odds, and put together their own forecasts, but that's not something we'll address; after that, I'll turn things over to Andrew so he can respond to your first question.

Andrew M. Callos

executive
#65

Right. So I mean, clearly, we're not going to be out there pushing or discussing a 15% to 20% uplift. For us to say anything about the data, we'd need to run further market research to gauge how that could shape use in HCM and what sort of spillover might exist, but I want to stress that we plan to stay strictly by-the-book when it comes to what our field colleagues can speak to.

Serge Belanger

analyst
#66

Hello, and good afternoon. I appreciate your taking my questions. I'll add to the discussion about ACACIA as well — it appears to be today's hot subject. So, I realize that nearly all of the data remains blinded to you, but I believe previously you mentioned keeping an eye on how much the endpoints vary. So I'm just wondering, based on whatever you're able to infer, has that variability shifted at all? Thank you.

Robert I. Blum

executive
#67

I'll direct this to Fady, though I want to stress once more that since we're now closer to the point of database lock and unblinding, we're unable to address a question like yours concerning standard deviation. What we can address instead is what the trial was built to show.

Fady Malik

executive
#68

The trial was set up so it could show a 5-point difference in KCCQ, with an assumed standard deviation of 15, along with a peak VO2 of 1 and a standard deviation of 3.

Robert I. Blum

executive
#69

Ninety percent power, with being able to detect statistically significant differences —

Fady Malik

executive
#70

When the gaps are smaller than that, the power is lower too, clearly. And like I said in the script, the study is still operating inside its design parameters, and, you know, we're not going to promise to update those statements later on.

Serge Belanger

analyst
#71

Understood. Thanks. Thanks.

Analyst

analyst
#72

Hello. Jackie here, filling in for Jason. Nice work on the momentum, and we appreciate you fielding our question. So, just quickly, could you share what you've observed so far in 2024 when it comes to patient start forms, and also roughly what portion of your initial activity has centered on more community practices, and how has adoption looked specifically in those offices? Thank you.

Robert I. Blum

executive
#73

Thanks. Andrew?

Andrew M. Callos

executive
#74

Okay. So we won't be providing figures — that's something we'll do during the first quarter call, in relation to start forms. What I can tell you is what we already stated in the script: our demand across those 3 weeks, along with the engagement we've observed with physicians, is at — or even beyond — our internal expectations. When it comes to community versus centers of excellence, the 700 physicians who made up 80% of the market — that's where most of it is originating. Yet we're also seeing robust engagement from the community. We're seeing robust engagement from new prescribers — likely new prescribers who have never written a CMI prescription — and those figures are exceeding what we had anticipated. So I'd say we're observing a healthy mix across every category of prescriber. And clearly, the bulk are those we're visiting and educating. On our first quarter call, we'll provide additional detail regarding patients and engagement — centers of excellence versus non-centers of excellence, prescribing depth, and so on. So, more will come, but with only 3 weeks of data, it's too soon to draw conclusions.

Robert I. Blum

executive
#75

I see. It is early innings, but we are pleased.

Robert I. Blum

executive
#76

Q (Alex (on behalf of Srikripa Devarakonda)): Hello there; Alex here, filling in for Kripa. Nice work on the advancement. It's really thrilling to think about how the REMS for MYCorzo might additionally enhance things for patients and physicians alike. One thing about that REMS: might there remain a path to revise what the REMS calls for down the road? Also, is it possible that Cytokinetics, Incorporated could return to the FDA at a later point with fresh post-marketing data and have it looked at again, perhaps making things even better?

Robert I. Blum

executive
#77

It's clear the FDA showed willingness to consider real-world evidence supporting a change to the Camzyos REMS; however, regarding our own REMS, no adjustments are being guided toward in the near term, though across a medium to longer horizon, it's fair to think real-world evidence might shape modifications. As for what form those modifications would take, saying so now would be jumping the gun. Fady or Stuart, is there anything else to include?

Fady Malik

executive
#78

When it comes to executing the REMS, the requirements are actually pretty simple, you know. Still, what we learn from real-world data is going to shape any possible changes down the road. That said, like Robert mentioned, it's still too early to say what we might go after. My sense is that we simply need real-world data to figure out where our pinch points may be and how that data could back up modifying the REMS in a way that eases those pinch points.

Analyst

analyst
#79

Hello. Natalie here, filling in for Ash, and we appreciate you answering our question once more; regarding ACACIA, might you explain what the rate of discontinuation looks like in ACACIA relative to earlier trials? Then, concerning the baseline patient population, can you tell us roughly what share of patients could possess the concentric LVH phenotypes?

Fady Malik

executive
#80

Discontinuations are something I can address; once more, the trial was built to tolerate a 10% rate of discontinuation, and as I believe I've mentioned previously, we have stayed inside that figure, and during my remarks earlier, I confirmed that again, though we won't promise to give an update on it in the future. Then, as you know, none of the baseline characteristics have been shared by us, so your final question is not one I can truly address. However, what I am able to state is that each echo belonging to every patient who enters the trial gets reviewed by our team of HCM specialist physicians, and if they do not consider an echo to be consistent with hypertrophic cardiomyopathy, a query would be sent to the site so that additional information could be collected that may back up the diagnosis.

Leonid Timashev

analyst
#81

Hi, everyone. I appreciate you taking my question. I'd like to circle back to the MYCorzo launch and patient starts. I'm wondering if you could share any detail about the kinds of patients being started, compared with what you'd anticipate from the initial mavacamten launch. Is there anything particular about the patients being put on therapy? Are these only new patients? Are there any switches happening? Is it patients who perhaps required greater efficacy or had a lower baseline ejection fraction? I'm just curious how physicians are approaching initial use of aficamten, now that they have the ability to prescribe the drug. Thank you.

Robert I. Blum

executive
#82

Good evening. Thank you. Just bear in mind that we don't always have visibility into patient-level data, and what we hear tends to be more anecdotal. I think "all of the above" might be one way to answer your question. But perhaps, Andrew, there's something else you'd like to add.

Andrew M. Callos

executive
#83

No. I believe you captured precisely what I intended to express, which is that information about patients is safeguarded; we aren't able to observe specifically who receives treatment or why. You know, it's too soon with the data to determine whether switching is occurring, and so on. However, I do believe we're witnessing all of the above, just as Robert mentioned.

Robert I. Blum

executive
#84

I appreciate that, operator, and I want to thank each of you for being with us on today's call. It goes without saying that we spent time thinking about how much this moment matters. Rather than going over those remarks again, let me simply state that we grasp what turning toward commercialization means, and our aim is to act rightly toward these patients — for the good of their treatment — and to act rightly toward the health care professionals who look after them. We likewise understand and appreciate that this represents a major milestone for Wall Street, since Cytokinetics, Incorporated has become a worldwide commercial enterprise, and we treat that responsibility with great seriousness too. We are eager to give you insight as more meaningful details emerge regarding the MYCorzo launch in the United States, the anticipated launch in Germany along with other European nations, and over the rest of this year we will learn more and be in a position to reveal more. Beyond that, with results from ACACIA becoming available, which we expect in Q2, we are eager to share them with all of you, and we appreciate how much those matter as well. So thank you for the interest you show and the attention you give to everything we are doing at Cytokinetics, Incorporated. We are eager to keep you informed about our progress. With that, operator, we are ready to bring the call to a close.

Operator

operator
#85

Everyone, that wraps up the conference call for today. We appreciate you joining, and you’re free to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.